Xaluprine contains a medicine called mercaptopurine, which works by stopping cancer cells from multiplying.
XALUPRINE® Oral Suspension 20mg/ml (mercaptopurine monohydrate) is the first oral suspension of mercaptopurine, indicated for the treatment of Acute Lymphoblastic Leukemia (ALL) in adults, adolescents and children. With Xaluprine® it is possible to give children an accurate and consistent dose of mercaptopurine according to body surface. The present splitting and crushing of tablets leading to problems of administration and compliance is avoided. Xaluprine® offer healthcare professionals and relatives a safer and better environment during preparation due to the lack of exposure to cytotoxic and mutagenic mercaptopurine dust.
100 ml glass bottle. Two dosing syringes of 1ml and 5 ml respectively are added to the pack.
Pharmanovia is the exclusive distributor in the Nordic and Baltic area.
Summary of Product Characteristics
As the product is approved by The European Medicines Agency (EMA) in all EU member states, the SPC can be found in each of the member state languages on the following website under ‘Product Information’:
Please note that the product has changed name from ‘Mercaptopurine Nova Laboratories’ to ‘Xaluprine’, which has not yet been corrected on the EMA website.
For more information
Whilst the Patient Information Leaflets (PIL) and Summary of Product Characteristics (SmPC) product information is intended to be helpful, we stress that this is not intended to, and should not, replace the advice of a qualified medical professional.
If you experience any side effects that cause you concern as a result of the use of any of our products and wish to notify us directly please get in touch via our contact page.
Please note that the above links are relevant to the local marketing authorisation requirements only. Patients and carers in Denmark can find similar information at www.medicin.dk however, if you are from outside Denmark, your local country requirements may differ. Please refer to your local country patient information leaflet(PIL) or summary product characteristic (SPC), if you are a patient or health care professional (HCP) respectively, for further guidance.